甘肃医药2026，Vol.45Issue(7)：600-603,4.DOI:10.15975/j.cnki.1004-2725.2026.07.006
乳腺癌中HR、HER2和Ki-67联合检测在不同分子亚型中的预后预测价值分析
Analysis of the prognostic predictive value of combined detection of HR,HER2,and Ki-67 in different molecular subtypes of breast cancer
摘要
Abstract
Objective:To evaluate the prognostic value of combined detection of hormone receptor(HR),human epidermal growth factor receptor 2(HER2),and Ki-67 proliferation index in different molecular subtypes of breast cancer.Methods:A total of 120 breast cancer patients treated from January 2020 to June 2025 were retrospectively included and divided into four groups according to molecular subtypes:Luminal A,Luminal B,HER2-overexpressing,and triple-negative,with 30 cases in each group.The expression differences of molecular markers across subtypes and their associations with prognosis were analyzed.The diagnostic efficacy of combined detection was as-sessed using receiver operating characteristic(ROC)curves.Results:Significant differences in the expression of HR,HER2,and Ki-67 were observed among molecular subtypes(P<0.05).Survival analysis revealed significantly different prognoses across subtypes(P<0.05),with the Luminal A subtype showing the best and the triple-negative subtype the worst outcomes.Multivariate Cox regression analysis confirmed that HER2 positivity,high Ki-67 expression and HR positivity were independent risk factors for disease-free survival.ROC curve analysis further demonstrated that the combined detection of the three markers was significantly superior to any single indicator(P<0.05).Conclusions:The combined detection of HR,HER2,and Ki-67 demonstrated significant prognostic value in different molecular subtypes of breast cancer,partic-ularly in high-risk subtypes,and may enhance the accuracy of recurrence and survival prediction,thereby guiding individualized treatment.关键词
乳腺癌/分子亚型/激素受体/人类表皮生长因子受体2/Ki-67增殖指数/联合检测Key words
breast cancer/molecular subtype/hormone receptor/human epidermal growth factor receptor 2/ki-67 proliferation in-dex/combined detection分类
医药卫生引用本文复制引用
刘俊林,郑杰,姚佳,吴双..乳腺癌中HR、HER2和Ki-67联合检测在不同分子亚型中的预后预测价值分析[J].甘肃医药,2026,45(7):600-603,4.基金项目
荆门市科学技术研究与开发计划引导项目(编号:2025YDKY076) （编号:2025YDKY076）
